New era, new GOALs: cardiovascular screening and lipid management in cystic fibrosis
Background: Cardiovascular disease (CVD) risks are increasing in people with cystic fibrosis (pwCF). While cholesterol levels were historically low in pwCF, higher levels after initiating highly effective modulator therapy (HEMT) have been reported. Mechanisms are unclear and there is little guidanc...
Saved in:
Main Authors: | Katherine A. Despotes, Agathe S. Ceppe, Jennifer L. Goralski, Scott H. Donaldson |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-02-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/17534666251317200 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A new era of cystic fibrosis therapy with CFTR modulators
by: Laura Gomes Boabaid de Barros, et al.
Published: (2025-01-01) -
New Developments in Cystic Fibrosis Airway Inflammation
by: Nades Palaniyar, et al.
Published: (2015-01-01) -
Psychosocial and mental health in cystic fibrosis in the modern era of care: time to evolve
by: Beth Smith, et al.
Published: (2025-02-01) -
Inflammation in Cystic Fibrosis
Published: (1996-01-01) -
Lobectomy in Patients with Cystic Fibrosis
by: Shahid I Sheikh, et al.
Published: (2014-01-01)